1. |
Song JL, Chen C, Yuan JP, et al. Progress in the clinical detection of heterogeneity in breast cancer. Cancer Med, 2016, 5(12): 3475-3488.
|
2. |
刘晓东, 佟仲生, 李淑芬, 等. 局部晚期乳腺癌 1 081 例临床病理特征及预后分析. 肿瘤, 2011, 31(10): 918-923.
|
3. |
Simos D, Clemons M, Ginsburg OM, et al. Definition and consequences of locally advanced breast cancer. Curr Opin Support Palliat Care, 2014, 8(1): 33-38.
|
4. |
Franceschini G, Terribile D, Magno S, et al. Update in the treatment of locally advanced breast cancer: a multidisciplinary approach. Eur Rev Med Pharmacol Sci, 2007, 11(5): 283-289.
|
5. |
Balogun OD, Formenti SC. Locally advanced breast cancer - strategies for developing nations. Front Oncol, 2015, 5: 89.
|
6. |
陈美慧, 钟媚共, 蒋旭, 等. 乳腺癌基因分型与患者临床病理及预后的关系. 肿瘤防治研究, 2018, 45(10): 752-757.
|
7. |
Grybach SM, Polishchuk LZ, Chekhun VF. Analysis of the survival of patients with breast cancer depending on age, molecular subtype of tumor and metabolic syndrome. Exp Oncol, 2018, 40(3): 243-248.
|
8. |
薛卫成. 介绍乳腺癌TNM分期系统(第 7 版). 诊断病理学杂志, 2010, 17(4): 241-244.
|
9. |
令狐锐霞, 司文, 李莹, 等. 3 846 例乳腺癌流行病学及临床病理学分析. 解放军医学院学报, 2015, 36(10): 1017-1021, 1038.
|
10. |
DeSantis CE, Ma J, Goding Sauer A, et al. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin, 2017, 67(6): 439-448.
|
11. |
郭俊字, 黎骋. 乳腺癌不同分子分型的临床病理特征及预后分析. 医学理论与实践, 2017, 30(3): 421-423.
|
12. |
Subramaniam DS, Isaacs C. Utilizing prognostic and predictive factors in breast cancer. Curr Treat Options Oncol, 2005, 6(2): 147-159.
|
13. |
沈镇宙, 夏川江. 乳腺癌肿瘤体积、淋巴结情况与预后的关系. 中华外科杂志, 1991, 29(9): 554-557.
|
14. |
邵志敏, 沈镇宙. 乳腺癌的预后因素研究进展. 中国癌症杂志, 2001, 11(5): 15-19.
|
15. |
Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer, 1989, 63(1): 181-187.
|
16. |
赵卫红, 徐兵河. 淋巴结阳性乳腺癌的术后辅助化疗研究进展. 癌症进展, 2005, 3(3): 232-236.
|
17. |
Hayward JL, Carbone PP, Rubens RD, et al. Assessment of response to therapy in advanced breast cancer (an amendment). Br J Cancer, 1978, 38(1): 201.
|
18. |
李雪梅. 乳腺癌分子分型在新辅助化疗疗效和预后中的预测作用. 中国继续医学教育, 2018, 10(15): 80-82.
|
19. |
Iqbal J, Shafi AA, Alharthi BN. Neoadjuvant chemotherapy in locally advanced breast cancer. J Coll Physicians Surg Pak, 2014, 24(11): 845-848.
|
20. |
Bhattacharyya T, Sharma SC, Yadav BS, et al. Outcome of neoadjuvant chemotherapy in locally advanced breast cancer: a tertiary care centre experience. Indian J Med Paediatr Oncol, 2014, 35(3): 215-220.
|
21. |
杨虹, 曾福仁, 田晓彩, 等. 分子分型与乳腺癌新辅助化疗疗效的相关性. 现代肿瘤医学, 2017, 25(16): 2585-2587.
|
22. |
Haque W, Verma V, Hatch S, et al. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat, 2018, 170(3): 559-567.
|
23. |
张彦武, 常庆龙, 贾国丛. NCT 不敏感的局部晚期乳腺癌的新辅助内分泌治疗疗效分析. 中国普通外科杂志, 2010, 19(5): 569-571.
|
24. |
Charehbili A, Fontein DB, Kroep JR, et al. Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: a systematic review. Cancer Treat Rev, 2014, 40(1): 86-92.
|
25. |
杨嘉媛, 张喜平. 局部晚期乳腺癌新辅助化疗疗效评价方式的研究进展. 现代肿瘤医学, 2019, 27(19): 3534-3538.
|
26. |
张玲菡, 柳梅, 龚灿, 等. 新辅助化疗后乳腺癌保乳手术问题现状. 中国普外基础与临床杂志, 2018, 25(2): 154-160.
|
27. |
桑晓旻. 局部晚期乳腺癌的生存分析和预后影响因素的研究. 天津: 天津医科大学, 2010.
|
28. |
Kwak HY, Chae BJ, Eom YH, et al. Is adjuvant chemotherapy omissible in women with T1-2 stage, node-positive, luminal A type breast cancer? J Chemother, 2015, 27(5): 290-296.
|
29. |
Park S, Lee SK, Paik HJ, et al. Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer. Medicine (Baltimore), 2017, 96(22): e6777.
|